On the Impact of Therapeutic Tumor Necrosis Factor-alpha Inhibition on Anogenital Human Papillomavirus Infection

• Status: Completed
• Trial end date: 2011-01-01
• Target enrollment: 0
• Participant gender: All

Summary

In this prospective, open, controlled, cross-sectional observational study patients with psoriasis or IBD, who received either anti-TNF-alpha inhibitors or alternates (purine-, folic acid analogues, phototherapy, fumaric ester, mesalazine) for their underlying disease were included.

Anogenital HPV-induced lesions, mucosal HPV DNA and serological status of mucosal low-risk (HPV6) and high-risk HPV (HPV16, HPV18) were determined.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Medical University of Vienna
• Treatments: 6-Mercaptopurine; Adalimumab; Etanercept; Folic Acid; Folic Acid Antagonists; Infliximab; Mercaptopurine; Mesalamine; Methotrexate; Sulfasalazine; Vitamin B Complex

Criteria

Inclusion Criteria:

• Participants between 18-80 years of age with a history of psoriasis or inflammatory bowel diseases, namely Crohn's disease and ulcerative colitis, and

• at least 6 month of continuous treatment regimen.

Exclusion Criteria:

• Pregnant or nursing patients and

• patients with inherited immune disorders, human immunodeficiency virus infection, invasive malignancies or psychomotor retardation and

• patients with psoriasis or inflammatory bowel diseases who had received high-dose corticosteroids during the past 6 months.